PER-034-13未知未知
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF 10 MG ONCE DAILY BILASTINE IN CHILDREN FROM 2 TO 11 YEARS OF AGE WITH EITHER ALLERGIC RHINOCONJUNCTIVITIS OR CHRONIC URTICARIA.
FAES FARMA SA,0 个研究点目标入组 0 人开始时间: 2013年11月26日最近更新:
试验速览
- 阶段
- 未知
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 至 11（—）
入选标准
- •(1) Boys and girls between 2 and 11 years old, inclusive, at screening.
- •(2) Documented history of allergic rhinoconjunctivitis (AR) or chronic urticaria (CU) with clinical symptoms at study entry.
- •(3) For AR patients, a positive skin prick test/RAST for at least one allergen.
- •(4) A 12 lead ECG obtained at screening within acceptable limits, moreover in absence of any drug effect or disease, QTc interval values (msec) after Fridericia’s correction must be normal (not prolonged). The values considered to be normal are 440 msec.
- •(5) Children who have written consent from their parent(s)/guardian to participate in the study. Children should be informed according to their understanding (assent form will be obtained whenever possible).
排除标准
- •(1)Non-allergic rhinitis or acute urticaria.
- •(2)Intake of particular medications with antiallergenic activities or sedative properties.
- •(3)Known allergy/hypersensitivity to the study drug (bilastine) or its inactive ingredients.
- •(4)Patients who are taking or have taken any of the following medications prior to randomisation in the study and have not complied with the specified washout period of 7 days unless otherwise noted:
- •Oral corticosteroids.
- •Antihistamines: Loratadine/ desloratadine (10 days) other systemic antihistamines (3 days).
- •Anti-leukotrienes.
- •Delayed-release corticosteroids (3 months).
- •Ketotifen (2 weeks).
- •Macrolides antibiotics and imidazolic antifungals (systemic).
- •Anticholinergics.
- •Investigational medication or antibodies.
- •Regular schedule immunotherapy can be maintained throughout the study but will be disallowed from 24h prior to 24h after first study dosing.
- •(5)Clinically relevant abnormal laboratory values indicative of physical illness (including clinically significant ECG abnormalities as judged by the investigator; e.g. Wolff-Parkinson-White syndrome or long QT syndrome), or patient whose health could be harmed by their participation in the study at investigator criteria.
- •(6)Hypersensitivity to H1 antihistamines or benzimidazoles.
- •(7)Any clinical conditions or relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, haematological, endocrine or neurological diseases that in the opinion of the investigator would make the subject unsuitable for the study or interfere with the aim of the study.
- •(8)Children or parent(s) unable to comply with the study requirements (attendance to visits), unable to take the study treatment, or children that should have to travel to another geographic area during the course of the study.
- •(9)Girl who is pregnant or lactating.
- •(10)Children who have a recent history (within previous 12 months) of drug addiction or alcohol abuse.
- •(11)Participation in another clinical study within 30 days prior to the first study drug intake.
研究者
相似试验
进行中（未招募）
1 期
EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS =1 MONTH TO <4 YEARS WITH PARTIAL-ONSET SEIZURESEpilepsy with partial onset seizuresMedDRA version: 21.0Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-000717-20-Outside-EU/EEACB Biosciences Inc.255
进行中（未招募）
1 期
EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS =1 MONTH TO <4 YEARS WITH PARTIAL-ONSET SEIZURESEUCTR2013-000717-20-BGCB Biosciences Inc.255
进行中（未招募）
1 期
EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS =1 MONTH TO <4 YEARS WITH PARTIAL-ONSET SEIZURESEpilepsy with partial onset seizuresMedDRA version: 20.0Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-000717-20-PLCB Biosciences Inc.244
进行中（未招募）
1 期
A Study of Idasanutlin with Cytarabine versus Cytarabine plus Placebo in Patients with Relapsed or Refractory Acute Myeloid Leukemia.Relapsed or refractory acute myeloid leukemia (AML).MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2014-003065-15-BEF. Hoffmann-La Roche Ltd440
进行中（未招募）
1 期
EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS >=1 MONTH TO <4 YEARS WITH PARTIAL-ONSET SEIZURESEUCTR2013-000717-20-ESCB Biosciences Inc.244